PFNX News and Press, Pfenex Inc. From 06/12/20

Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States The first FDA-approved teriparatide with Forteo® 1-3  as the reference drug SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American...

SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William Blair Growth Stock Conference on June 9, 2020.  The discussion will be vir...

Image source: The Motley Fool. Pfenex   (NYSEMKT: PFNX) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading

Pfenex Inc. (PFNX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Eef Schimmelpennink – President and Chief Executive Officer Conference Call Participants Greg Gilbert – SunTrust Brandon Folkes – Cantor Fitzgerald Jason But...

Pfenex (NYSEMKT: PFNX ): Q1 GAAP EPS of -$0.31 misses by $0.07 . Revenue of $0.68M (-91.3% Y/Y) misses by $3.81M . Press Release More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex Expression Technology®, to develop next generation and novel protein therapeutics...

SAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 7, 2020. Pfenex will host a conference call and webcast to discuss it...

Athersys (NASDAQ: ATHX ) initiated with Outperform rating and $14 (528% upside) price target at SMBC Nikko. More news on: Athersys, Inc., Livongo Health, Inc., Pfenex Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Janssen Signs Collaboration with ImmunoPrecise Antibodies Johnson & Johnson ( JNJ ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. ( IPATF ). The new deal offers Janssen an exclusive access to an array of novel...

NEW YORK , April 17, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pfenex Inc. ("Pfenex" or "the Company") (NASDAQ: PFNX). Investors who purchased Pfenex securities&...